WP
PHVS icon

Woodline Partners’s Pharvaris PHVS Stock Holding History

Woodline Partners’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$2.5M – 1094
2025
Q3 		$2.5M Buy
+100,000
New +$2.22M 0.01% 696
2025
Q1 		– Sell
-44,514
Closed -$853K – 1002
2024
Q4 		$853K Buy
+44,514
New +$916K 0.01% 782

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Woodline Partners's PHVS Position: Q4 2025 in Review

Woodline Partners sold out of Pharvaris (PHVS) in Q4 2025, closing a stake of 100,000 shares — an estimated $2.5M sold.

Woodline Partners first reported a position in PHVS in Q4 2024 and held it in 2 quarters. The position peaked at $2.5M in Q3 2025. 106 funds tracked by Wall St. Rank hold PHVS as of Q4 2025.

  • Woodline Partners reported no remaining Pharvaris position as of Q4 2025 after selling out during the quarter.
  • Woodline Partners sold 100,000 Pharvaris shares in Q4 2025, an estimated $2.5M.
  • Woodline Partners first reported a position in Pharvaris in Q4 2024 and held it in 2 quarters.
  • Woodline Partners's Pharvaris position peaked at $2.5M in Q3 2025.
  • 106 funds tracked by Wall St. Rank held Pharvaris as of Q4 2025.

Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.